journal article·2025-05-12

RNA–lipid nanoparticles for acute critical illnesses

Serena Omo-Lamai, Marco E. Zamora, Bernhard K. Mueller, Jessica C. Casciano, Jacob S. Brenner

Nature Reviews Bioengineering· Volume 3· Issue 9
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior · Hepatitis Viruses Studies and Epidemiology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Yeh, T.-F., Lin, C. & Sung, H.-C. A review of technological developments in lipid nanoparticle application for mRNA vaccination. Hum. Vaccin. Immunother. 19, 2256040 (2023).10.1080/21645515.2023.2256040 ↗
2. Jeong, M., Lee, Y., Park, J., Jung, H. & Lee, H. Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications. Adv. Drug Deliv. Rev. 200, 114990 (2023).10.1016/j.addr.2023.114990 ↗
3. Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).10.1038/s41392-022-01007-w ↗
4. Seo, Y. et al. Recent progress of lipid nanoparticles-based lipophilic drug delivery: focus on surface modifications. Pharmaceutics 15, 772 (2023).10.3390/pharmaceutics15030772 ↗
5. Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).10.1056/NEJMoa1716153 ↗
6. Urits, I. et al. A review of patisiran (ONPATTRO®) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol. Ther. 9, 301–315 (2020).10.1007/s40120-020-00208-1 ↗
7. Fortner, A. & Schumacher, D. First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization. Discoveries 9, e122 (2021).10.15190/d.2021.1 ↗
8. Cyranoski, D. Why emergency COVID-vaccine approvals pose a dilemma for scientists. Nature 588, 18–19 (2020).10.1038/d41586-020-03219-y ↗
9. Precision Nanosystems. RNA-LNPs: Navigating the Regulatory Challenges. https://www.pharmaceutical-technology.com/sponsored/rna-lnps-navigating-the-regulatory-challenges/ (2023).
10. Centers for Disease Control and Prevention. Leading Causes of Death https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm (2024).
11. Centers for Disease Control and Prevention. Cancer Deaths — Health, United States https://www.cdc.gov/nchs/hus/topics/cancer-deaths.htm (2023).
12. Lüscher, T. F. Lumpers and splitters: the bumpy road to precision medicine. Eur. Heart J. 40, 3292–3296 (2019).10.1093/eurheartj/ehz644 ↗
13. Dhir, N. et al. Pre-clinical to clinical translational failures and current status of clinical trials in stroke therapy: a brief review. Curr. Neuropharmacol. 18, 596–612 (2020).10.2174/1570159X18666200114160844 ↗
14. Morales Castro, D., Dresser, L., Granton, J. & Fan, E. Pharmacokinetic alterations associated with critical illness. Clin. Pharmacokinet. 62, 209–220 (2023).10.1007/s40262-023-01213-x ↗
15. Hwang, T. J. et al. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern. Med. 176, 1826–1833 (2016).10.1001/jamainternmed.2016.6008 ↗
16. Maslove, D. M. et al. Redefining critical illness. Nat. Med. 28, 1141–1148 (2022).10.1038/s41591-022-01843-x ↗
17. Liu, P. et al. Subphenotyping heterogeneous patients with chronic critical illness to guide individualised fluid balance treatment using machine learning: a retrospective cohort study. EClinicalMedicine 59, 101970 (2023).10.1016/j.eclinm.2023.101970 ↗
18. Pirracchio, R. & Gropper, M. A. Heterogeneity in intensive care: low severity does not mean low risk! Anesthesiology 130, 190–191 (2019).10.1097/ALN.0000000000002537 ↗
19. Leligdowicz, A. & Matthay, M. A. Heterogeneity in sepsis: new biological evidence with clinical applications. Crit. Care 23, 80 (2019).10.1186/s13054-019-2372-2 ↗
20. Capra, E. et al. What early-stage investing reveals about biotech innovation. McKinsey & Company https://www.mckinsey.com/industries/life-sciences/our-insights/what-early-stage-investing-reveals-about-biotech-innovation (2023).
21. Quentin, W. et al. How Denmark, England, Estonia, France, Germany, and the USA pay for variable, specialized and low volume care: a cross-country comparison of in-patient payment systems. Int. J. Health Policy Manag. 11, 2940–2950 (2022).
22. Heine, R. et al. Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future. HemaSphere 5, e524 (2021).10.1097/HS9.0000000000000524 ↗
23. Villar, J. et al. Unsuccessful and successful clinical trials in acute respiratory distress syndrome: addressing physiology-based gaps. Front. Physiol. 12, 774025 (2021).10.3389/fphys.2021.774025 ↗
24. Radloff, K. et al. Cationic LNP-formulated mRNA expressing Tie2-agonist in the lung endothelium prevents pulmonary vascular leakage. Mol. Ther. Nucleic Acids 34, 102068 (2023).10.1016/j.omtn.2023.102068 ↗
25. Sun, H. et al. Application of lung-targeted lipid nanoparticle-delivered mRNA of soluble PD-L1 via SORT technology in acute respiratory distress syndrome. Theranostics 13, 4974–4992 (2023).10.7150/thno.86466 ↗
26. Tang, C. et al. mRNA-laden lipid-nanoparticle-enabled in situ CAR-macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model. ACS Nano 18, 2261–2278 (2024).10.1021/acsnano.3c10109 ↗
27. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT05659264 (2025).
28. Pires, D. E. V., Blundell, T. L. & Ascher, D. B. PkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58, 4066–4072 (2015).10.1021/acs.jmedchem.5b00104 ↗
29. Jang, G. R., Harris, R. Z. & Lau, D. T. Pharmacokinetics and its role in small molecule drug discovery research. Med. Res. Rev. 21, 382–396 (2001).10.1002/med.1015 ↗
30. Sharma, A. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154, 123–140 (1997).10.1016/S0378-5173(97)00135-X ↗
31. Li, T., Cipolla, D., Rades, T. & Boyd, B. J. Drug nanocrystallisation within liposomes. J. Control. Release 288, 96–110 (2018).10.1016/j.jconrel.2018.09.001 ↗
32. Liu, P., Chen, G. & Zhang, J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules 27, 1372 (2022).10.3390/molecules27041372 ↗
33. Porello, I. & Cellesi, F. Intracellular delivery of therapeutic proteins. New advancements and future directions. Front. Bioeng. Biotechnol. 11, 1211798 (2023).10.3389/fbioe.2023.1211798 ↗
34. Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655–672 (2014).10.1038/nrd4363 ↗
35. Scaletti, F. et al. Protein delivery into cells using inorganic nanoparticle-protein supramolecular assemblies. Chem. Soc. Rev. 47, 3421–3432 (2018).10.1039/C8CS00008E ↗
36. Rahban, M. et al. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry. RSC Adv. 13, 35947–35963 (2023).10.1039/D3RA06476J ↗
37. Wu, J., Sahoo, J. K., Li, Y., Xu, Q. & Kaplan, D. L. Challenges in delivering therapeutic peptides and proteins: a silk-based solution. J. Control. Release 345, 176–189 (2022).10.1016/j.jconrel.2022.02.011 ↗
38. Ball, R. L., Hajj, K. A., Vizelman, J., Bajaj, P. & Whitehead, K. A. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. Nano Lett. 18, 3814–3822 (2018).10.1021/acs.nanolett.8b01101 ↗
39. van der Meel, R. et al. Modular lipid nanoparticle platform technology for siRNA and lipophilic prodrug delivery. Small 17, e2103025 (2021).10.1002/smll.202103025 ↗
40. Kularatne, R. N., Crist, R. M. & Stern, S. T. The future of tissue-targeted lipid nanoparticle-mediated nucleic acid delivery. Pharmaceuticals 15, 897 (2022).10.3390/ph15070897 ↗
41. Nakamura, T. et al. Extrahepatic targeting of lipid nanoparticles in vivo with intracellular targeting for future nanomedicines. Adv. Drug Deliv. Rev. 188, 114417 (2022).10.1016/j.addr.2022.114417 ↗
42. Xiao, Y. & Shi, J. Lipids and the emerging RNA medicines. Chem. Rev. 121, 12109–12111 (2021).10.1021/acs.chemrev.1c00778 ↗
43. Eygeris, Y., Gupta, M., Kim, J. & Sahay, G. Chemistry of lipid nanoparticles for RNA delivery. ACC Chem. Res. 55, 2–12 (2022).10.1021/acs.accounts.1c00544 ↗
44. Rietwyk, S. & Peer, D. Next-generation lipids in RNA interference therapeutics. ACS Nano 11, 7572–7586 (2017).10.1021/acsnano.7b04734 ↗
45. Landesman-Milo, D. & Peer, D. Toxicity profiling of several common RNAi-based nanomedicines: a comparative study. Drug Deliv. Transl. Res. 4, 96–103 (2014).10.1007/s13346-013-0158-7 ↗
46. Peer, D. Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 64, 1738–1748 (2012).10.1016/j.addr.2012.06.013 ↗
47. Chatterjee, S., Kon, E., Sharma, P. & Peer, D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl Acad. Sci. USA 121, e2307800120 (2024).10.1073/pnas.2307800120 ↗
48. Gilleron, J. et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638–646 (2013).10.1038/nbt.2612 ↗
49. Ma, D. Enhancing endosomal escape for nanoparticle mediated siRNA delivery. Nanoscale 6, 6415–6425 (2014).10.1039/c4nr00018h ↗
50. Pattipeiluhu, R. et al. Liquid crystalline inverted lipid phases encapsulating siRNA enhance lipid nanoparticle mediated transfection. Nat. Commun. 15, 1303 (2024).10.1038/s41467-024-45666-5 ↗
51. Philipp, J. et al. pH-dependent structural transitions in cationic ionizable lipid mesophases are critical for lipid nanoparticle function. Proc. Natl Acad. Sci. USA 120, e2310491120 (2023).10.1073/pnas.2310491120 ↗
52. Eygeris, Y., Patel, S., Jozic, A. & Sahay, G. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 20, 4543–4549 (2020).10.1021/acs.nanolett.0c01386 ↗
53. Heyes, J., Palmer, L., Bremner, K. & MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107, 276–287 (2005).10.1016/j.jconrel.2005.06.014 ↗
54. Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).10.1038/s41467-021-27493-0 ↗
55. Cheng, X. & Lee, R. J. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv. Drug Deliv. Rev. 99, 129–137 (2016).10.1016/j.addr.2016.01.022 ↗
56. Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022).10.1016/j.addr.2022.114416 ↗
57. Wilson, B. & Geetha, K. M. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J. Drug Deliv. Sci. Technol. 74, 103553 (2022).10.1016/j.jddst.2022.103553 ↗
58. Kawaguchi, M. et al. Effect of cholesterol content of lipid composition in mRNA-LNPs on the protein expression in the injected site and liver after local administration in mice. J. Pharm. Sci. 112, 1401–1410 (2023).10.1016/j.xphs.2022.12.026 ↗
59. Patel, S. et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 11, 983 (2020).10.1038/s41467-020-14527-2 ↗
60. Wang, M. M. et al. Elucidation of lipid nanoparticle surface structure in mRNA vaccines. Sci. Rep. 13, 16744 (2023).10.1038/s41598-023-43898-x ↗
61. Berger, M. et al. Effect of PEG anchor and serum on lipid nanoparticles: development of a nanoparticles tracking method. Pharmaceutics 15, 597 (2023).10.3390/pharmaceutics15020597 ↗
62. Sarode, A. et al. Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing. Nanoscale Adv. 4, 2107–2123 (2022).10.1039/D1NA00712B ↗
63. Lee, Y., Jeong, M., Park, J., Jung, H. & Lee, H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp. Mol. Med. 55, 2085–2096 (2023).10.1038/s12276-023-01086-x ↗
64. Tenchov, R., Sasso, J. M. & Zhou, Q. A. PEGylated lipid nanoparticle formulations: Immunological safety and efficiency perspective. Bioconjug. Chem. 34, 941–960 (2023).10.1021/acs.bioconjchem.3c00174 ↗
65. Parhiz, H. et al. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. J. Control. Release 291, 106–115 (2018).10.1016/j.jconrel.2018.10.015 ↗
66. Tombácz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol. Ther. 29, 3293–3304 (2021).10.1016/j.ymthe.2021.06.004 ↗
67. Lokugamage, M. P. et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat. Biomed. Eng. 5, 1059–1068 (2021).10.1038/s41551-021-00786-x ↗
68. Del Sorbo, L. & Slutsky, A. S. Acute respiratory distress syndrome and multiple organ failure. Curr. Opin. Crit. Care 17, 1–6 (2011).
69. Silva, P. L., Pelosi, P. & Rocco, P. R. M. Personalized pharmacological therapy for ARDS: a light at the end of the tunnel. Expert Opin. Investig. Drugs 29, 49–61 (2020).10.1080/13543784.2020.1699531 ↗
70. Wilson, J. G. & Calfee, C. S. in Annual Update in Intensive Care and Emergency Medicine 2020 (ed Vincent, J.-L.) 67–79 (Springer International Publishing, 2020).10.1007/978-3-030-37323-8_5 ↗
71. Rezoagli, E. et al. Presence of comorbidities alters management and worsens outcome of patients with acute respiratory distress syndrome: insights from the LUNG SAFE study. Ann. Intensive Care 12, 42 (2022).10.1186/s13613-022-01015-7 ↗
72. Melamed, J. R. et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer. Sci. Adv. 9, eade1444 (2023).10.1126/sciadv.ade1444 ↗
73. Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).10.1073/pnas.2109256118 ↗
74. Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).10.1038/s41565-020-0669-6 ↗
75. Torchilin, V. P., Khaw, B. A., Smirnov, V. N. & Haber, E. Preservation of antimyosin antibody activity after covalent coupling to liposomes. Biochem. Biophys. Res. Commun. 89, 1114–1119 (1979).10.1016/0006-291X(79)92123-5 ↗
76. Heath, T. D., Fraley, R. T. & Papahdjopoulos, D. Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab’)2 to vesicle surface. Science 210, 539–541 (1980).10.1126/science.7423203 ↗
77. Gregoriadis, G. Targeting of drugs. Nature 265, 407–411 (1977).10.1038/265407a0 ↗
78. Zamora, M. E. et al. Combination of physicochemical tropism and affinity moiety targeting of lipid nanoparticles enhances organ targeting. Nano Lett. https://doi.org/10.1021/acs.nanolett.3c05031 (2024).10.1021/acs.nanolett.3c05031 ↗
79. Marcos-Contreras, O. A. et al. Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain. J. Control. Release 301, 54–61 (2019).10.1016/j.jconrel.2019.03.008 ↗
80. Ferrer, M. C. C. et al. ICAM-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLoS One 9, e102329 (2014).10.1371/journal.pone.0102329 ↗
81. Nong, J. et al. Targeting lipid nanoparticles to the blood brain barrier to ameliorate acute ischemic stroke. Mol. Ther. https://doi.org/10.1016/j.ymthe.2024.03.004 (2024).10.1016/j.ymthe.2024.03.004 ↗
82. Omo-Lamai, S. et al. Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury. PLoS One 19, e0297451 (2024).10.1371/journal.pone.0297451 ↗
83. Zamora, M. E. et al. Marginated neutrophils in the lungs effectively compete for nanoparticles targeted to the endothelium, serving as a part of the reticuloendothelial system. ACS Nano 18, 22275–22297 (2024).10.1021/acsnano.4c06286 ↗
84. Muzykantov, V. R. et al. Streptavidin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (platelet-endothelial cell adhesion molecule 1): a strategy for vascular immunotargeting of drugs. Proc. Natl Acad. Sci. USA 96, 2379–2384 (1999).10.1073/pnas.96.5.2379 ↗
85. Brenner, J. S., Greineder, C., Shuvaev, V. & Muzykantov, V. Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opin. Drug Deliv. 12, 239–261 (2015).10.1517/17425247.2015.961418 ↗
86. Marcos-Contreras, O. A. et al. Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier. Proc. Natl Acad. Sci. USA 117, 3405–3414 (2020).10.1073/pnas.1912012117 ↗
87. Asgeirsdóttir, S. A. et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am. J. Physiol. Renal Physiol. 294, F554–F561 (2008).10.1152/ajprenal.00391.2007 ↗
88. Feuerhake, F., Füchsl, G., Bals, R. & Welsch, U. Expression of inducible cell adhesion molecules in the normal human lung: immunohistochemical study of their distribution in pulmonary blood vessels. Histochem. Cell Biol. 110, 387–394 (1998).10.1007/s004180050299 ↗
89. Myerson, J. W. et al. Flexible nanoparticles reach sterically obscured endothelial targets inaccessible to rigid nanoparticles. Adv. Mater. 30, e1802373 (2018).10.1002/adma.201802373 ↗
90. Myerson, J. W. et al. Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation. Nat. Nanotechnol. 17, 86–97 (2022).10.1038/s41565-021-00997-y ↗
91. Wang, Z. et al. Combating complement’s deleterious effects on nanomedicine by conjugating complement regulatory proteins to nanoparticles. Adv. Mater. 34, e2107070 (2022).10.1002/adma.202107070 ↗
92. Wang, Z. & Brenner, J. S. The nano-war against complement proteins. AAPS J. 23, 105 (2021).10.1208/s12248-021-00630-9 ↗
93. Lopes dos Santos, M., Quintilio, W., Manieri, T. M., Tsuruta, L. R. & Moro, A. M. Advances and challenges in therapeutic monoclonal antibodies drug development. Braz. J. Pharm. Sci. 54, e01007 (2018).
94. Xu, L. et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1, 337–346 (2002).
95. Hood, E. D. et al. Vascular targeting of radiolabeled liposomes with bio-orthogonally conjugated ligands: single chain fragments provide higher specificity than antibodies. Bioconjug. Chem. 29, 3626–3637 (2018).10.1021/acs.bioconjchem.8b00564 ↗
96. Thomas, G. D. Effect of dose, molecular size, and binding affinity on uptake of antibodies. Methods Mol. Med. 25, 115–132 (2000).
97. Janeway, C. A., Jr, Travers, P., Walport, M. & Shlomchik, M. J. in Immunobiology: The Immune System in Health and Disease 5th edn (Garland Science, 2001).
98. Chames, P., Van Regenmortel, M., Weiss, E. & Baty, D. Therapeutic antibodies: successes, limitations and hopes for the future: therapeutic antibodies: an update. Br. J. Pharmacol. 157, 220–233 (2009).10.1111/j.1476-5381.2009.00190.x ↗
99. Wilkinson, I. et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS One 16, e0260954 (2021).10.1371/journal.pone.0260954 ↗
100. Yu, W. et al. Efficient labeling of native human IgG by proximity-based sortase-mediated isopeptide ligation. Bioconjug. Chem. 32, 1058–1066 (2021).10.1021/acs.bioconjchem.1c00099 ↗